This paper presents categorical data that were gathered at two urban clinics and two suburban clinics of Johns Hopkins in an effort to identify characteristics of young female patients who successfully complete the three-injection sequence of the Gardasil quadrivalent human papillomavirus vaccine (HPV4). Available categorical correlates included patient age group, patient race, clinic location ...

Volume 82, Number 12 www.aafp.org/afp American Family Physician 1541 The bivalent human papillomavirus (HPV) recombinant vaccine (Cervarix) is the second vaccine to be approved in the United States for the prevention of cervical cancer, cervical adenocarcinoma in situ, and cervical intraepithelial neoplasia (CIN) caused by HPV types 16 and 18.1 These HPV types currently cause 70 percent of all ...

Joint pain or arthralgia is a common complaint among girls who have received immunization with the human papillomavirus (HPV) vaccine, but the pathogenesis of this disorder has not been completely understood. We report 2 cases of joint lesions after HPV vaccination. In one case, a 13-yearold patient showed transient arthropathy in the right wrist joint after the first dose of Gardasil® administ...

The majority of cervical cancers result when the human papillomavirus (HPV) is transmitted from a man to a woman during vaginal intercourse. Several factors, including vaginal intercourse at an early age or with multiple sex partners, place women at increased risk for infection with HPV. It is important for physicians to be aware of these risk factors and to screen for them in all of their fema...

Cervical cancer, caused by oncogenic types of human papillomavirus (HPV), remains a major health problem worldwide. The recent introduction of a quadrivalent vaccine (Gardasil), which targets HPV strains responsible for approximately 70% of cervical cancer cases and 90% of genital warts, has ushered in new hope of substantially reducing global prevalence of HPV disease. A further bivalent HPV v...

GARDASIL has been shown to reduce the incidence of pre-cancerous cervical, vulvar, and vaginal lesions, and external genital warts causally related to HPV6/11/16/18. Because of its expected public health benefit on reduction of cervical cancer and other HPV-related diseases, this vaccine has been rapidly implemented in the routine vaccination programs of several countries. It is therefore essen...

OBJECTIVES To investigate the usage patterns and adherence rates with the quadrivalent HPV (qHPV) vaccine at Naval Medical Center San Diego. METHODS This retrospective, cross-sectional study was conducted by using AHLTA (Electronic Health Record of DoD) to identify all qHPV recipients between 2006 and 2009. Charts were reviewed to extract demographic variables and immunization schedules for a...

Globally, cervical cancer is one of the most deadly forms of cancer affectingwomen—killingmore than 270,000 people every year. Themajority of these deaths (85%, according to theWHO) occur in developing countries. A global health priority, therefore, is to provide low-cost, highly effective cervical cancer prevention, detection, and control options to all women who need them. The human papilloma...